[1]
|
Bray, F., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
https://doi.org/10.3322/caac.21492
|
[2]
|
Shoag, J., et al. (2016) Clinical Variability and Molecular Heterogeneity in Prostate Cancer. Asian Journal of Andrology, 18, 543-548. https://doi.org/10.4103/1008-682X.178852
|
[3]
|
Beroukhim, R., Mermel, C.H., Porter, D., et al. (2010) The Landscape of Somatic Copy-Number Alteration across Human Cancers. Nature, 463, 899-905.
|
[4]
|
Barbieri, C.E., et al. (2012) Exome Sequencing Identifies Recurrent SPOP, FOXA1 and MED12 Mutations in Prostate Cancer. Nature Genetics, 44, 685-689. https://doi.org/10.1038/ng.2279
|
[5]
|
Petroski, M.D. and Deshaies, R.J. (2005) Function and Regulation of cullin-RING Ubiquitin Ligases. Nature Reviews Molecular Cell Biology, 6, 9-20. https://doi.org/10.1038/nrm1547
|
[6]
|
Wang, Z., Liu, P., Inuzuka, H., et al. (2014) Roles of F-Box Proteins in Cancer. Nature Reviews Cancer, 14, 233-247.
https://doi.org/10.1038/nrc3700
|
[7]
|
Errington, W.J., Khan, M.Q., Bueler, S.A., et al. (2012) Adaptor Protein Self-Assembly Drives the Control of a Cullin-RING Ubiquitin Ligase. Structure, 20, 1141-1153. https://doi.org/10.1016/j.str.2012.04.009
|
[8]
|
Zhuang, M., Calabrese, M.F., Liu, J., et al. (2009) Structures of SPOP-Substrate Complexes: Insights into Molecular Architectures of BTB-Cul3 Ubiquitin Ligases. Molecular Cell, 36, 39-50. https://doi.org/10.1016/j.molcel.2009.09.022
|
[9]
|
Stogios, P.J., Downs, G.S., Jauhal, J.J., et al. (2005) Sequence and Structural Analysis of BTB Domain Proteins. Genome Biology, 6, R82. https://doi.org/10.1186/gb-2005-6-10-r82
|
[10]
|
El-Gebali, S., Mistry, J., Bateman, A., et al. (2019) The Pfam Protein Families Database in 2019. Nucleic Acids Research, 47, D427-D432. https://doi.org/10.1093/nar/gky995
|
[11]
|
Choo, K.B., Chuang, T.J., Lin, W.Y., et al. (2010) Evolutionary Expansion of SPOP and Associated TD/POZ Gene Family: Impact of Evolutionary Route on Gene Expression Pattern. Gene, 460, 39-47.
https://doi.org/10.1016/j.gene.2010.04.003
|
[12]
|
Kim, M.S., Je, E.M., Oh, J.E., et al. (2013) Mutational and Ex-pressional Analyses of SPOP, a Candidate Tumor Suppressor Gene, in Prostate, Gastric and Colorectal Cancers. APMIS, 121, 626-633. https://doi.org/10.1111/apm.12030
|
[13]
|
Berger, M.F., Lawrence, M.S., Demichelis, F., et al. (2011) The Genomic Complexity of Primary Human Prostate Cancer. Nature, 470, 214-220. https://doi.org/10.1038/nature09744
|
[14]
|
Beltran, H., Wyatt, A.W., Chedgy, E.C., et al. (2017) Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. Clinical Cancer Research, 23, 6802-6811. https://doi.org/10.1158/1078-0432.CCR-17-1034
|
[15]
|
Boysen, G., Rodrigues, D.N., Rescigno, P., et al. (2018) SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity. Clinical Cancer Research, 24, 5585-5593. https://doi.org/10.1158/1078-0432.CCR-18-0937
|
[16]
|
Blattner, M., Lee, D.J., O’Reilly, C., et al. (2014) SPOP Mutations in Prostate Cancer across Demographically Diverse Patient Cohorts. Neoplasia, 16, 14-20. https://doi.org/10.1593/neo.131704
|
[17]
|
Böttcher, R., Kweldam, C.F., Livingstone, J., et al. (2018) Cribriform and Intraductal Prostate Cancer Are Associated with Increased Genomic Instability and Distinct Genomic Alterations. BMC Cancer, 18, Article No. 8.
https://doi.org/10.1186/s12885-017-3976-z
|
[18]
|
Manson-Bahr, D., Ball, R., Gundem, G., et al. (2015) Mutation Detection in Formalin-Fixed Prostate Cancer Biopsies Taken at the Time of Diagnosis Using Next-Generation DNA Sequencing. Journal of Clinical Pathology, 68, 212-217.
https://doi.org/10.1136/jclinpath-2014-202754
|
[19]
|
Zuhlke, K.A., Johnson, A.M., Tomlins, S.A., et al. (2014) Identification of a Novel Germline SPOP Mutation in a Family with Hereditary Prostate Cancer. Prostate, 74, 983-990. https://doi.org/10.1002/pros.22818
|
[20]
|
Buckles, E., Qian, C., Tadros, A., et al. (2014) Identification of Speck-le-Type POZ Protein Somatic Mutations in African American Prostate Cancer. Asian Journal of Andrology, 16, 829-832. https://doi.org/10.4103/1008-682X.132470
|
[21]
|
Vinceneux, A., Bruyère, F., Haillot, O., et al. (2017) Ductal Adenocarcinoma of the Prostate: Clinical and Biological Profiles. Profile, 77, 1242-1250. https://doi.org/10.1002/pros.23383
|
[22]
|
Abeshouse, A., et al. (2015) The Molecular Taxonomy of Primary Prostate Cancer. Cell, 163, 1011-1025.
|
[23]
|
Li, C., Ao, J., Fu, J., et al. (2011) Tumor-Suppressor Role for the SPOP Ubiquitin Ligase in Signal-Dependent Proteolysis of the Oncogenic Co-Activator SRC-3/AIB1. Oncogene, 30, 4350-4364. https://doi.org/10.1038/onc.2011.151
|
[24]
|
An, J., Wang, C., Deng, Y., et al. (2014) Destruction of Full-Length Androgen Receptor by Wild-Type SPOP, But Not Prostate-Cancer-Associated Mutants. Cell Reports, 6, 657-669. https://doi.org/10.1016/j.celrep.2014.01.013
|
[25]
|
Geng, C., Rajapakshe, K., Shah, S.S., et al. (2014) Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate Cancer. Cancer Research, 74, 5631-5643.
https://doi.org/10.1158/0008-5472.CAN-14-0476
|
[26]
|
An, J., Ren, S., Murphy, S.J., et al. (2015) Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation. Molecular Cell, 59, 904-916.
https://doi.org/10.1016/j.molcel.2015.07.025
|
[27]
|
Zhang, J., Bu, X., Wang, H., et al. (2018) Cyclin D-CDK4 Ki-nase Destabilizes PD-L1 via Cullin 3-SPOP to Control Cancer Immune Surveillance. Nature, 553, 91-95. https://doi.org/10.1038/nature25015
|
[28]
|
Dai, X., Gan, W., Li, X., et al. (2017) Prostate Cancer-Associated SPOP Mutations Confer Resistance to BET Inhibitors through Stabilization of BRD4. Nature Medicine, 23, 1063-1071. https://doi.org/10.1038/nm.4378
|
[29]
|
Boysen, G., Barbieri, C.E., Prandi, D., et al. (2015) SPOP Mutation Leads to Genomic Instability in Prostate Cancer. Elife, 4, e09207. https://doi.org/10.7554/eLife.09207
|
[30]
|
Copeland, B.T., Du, J., Pal, S.K., et al. (2019) Factors That Influence the Androgen Receptor Cistrome in Benign and Malignant Prostate Cells. Molecular Oncology, 13, 2616-2632. https://doi.org/10.1002/1878-0261.12572
|
[31]
|
Tomlins, S.A., Rhodes, D.R., Perner, S., et al. (2005) Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer. Science, 310, 644-648. https://doi.org/10.1126/science.1117679
|
[32]
|
Nam, R.K., Sugar, L., Yang, W., et al. (2007) Expression of the TMPRSS2:ERG Fusion Gene Predicts Cancer Recurrence after Surgery for Localised Prostate Cancer. British Journal of Cancer, 97, 1690-1695.
https://doi.org/10.1038/sj.bjc.6604054
|
[33]
|
Shoag, J. and Barbieri, C.E. (2016) Clinical Variability and Molecular Heterogeneity in Prostate Cancer. Asian Journal of Andrology, 18, 543-548. https://doi.org/10.4103/1008-682X.178852
|
[34]
|
Gan, W., Dai, X., Lunardi, A., et al. (2015) SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression. Molecular Cell, 59, 917-930. https://doi.org/10.1016/j.molcel.2015.07.026
|
[35]
|
Blattner, M., Liu, D., Robinson, B.D., et al. (2017) SPOP Mutation Drives Prostate Tumorigenesis in Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. Cancer Cell, 31, 436-451.
https://doi.org/10.1016/j.ccell.2017.02.004
|
[36]
|
Shoag, J., Liu, D., Blattner, M., et al. (2018) SPOP Mutation Drives Prostate Neoplasia without Stabilizing Oncogenic Transcription Factor ERG. Journal of Clinical Investigation, 128, 381-386. https://doi.org/10.1172/JCI96551
|
[37]
|
Jeggo, P.A., Pearl, L.H. and Carr, A.M. (2016) DNA Repair, Genome Stability and Cancer: A Historical Perspective. Nature Reviews Cancer, 16, 35-42. https://doi.org/10.1038/nrc.2015.4
|
[38]
|
Hjorth-Jensen, K., Maya-Mendoza, A., Dalgaard, N., et al. (2018) SPOP Promotes Transcriptional Expression of DNA Repair and Replication Factors to Prevent Replication Stress and Genomic Instability. Nucleic Acids Research, 46, 9484-9495. https://doi.org/10.1093/nar/gky719
|
[39]
|
Zhang, D., Wang, H., Sun, M., et al. (2014) Speckle-Type POZ Protein, SPOP, Is Involved in the DNA Damage Response. Carcinogenesis, 35, 1691-1697. https://doi.org/10.1093/carcin/bgu022
|
[40]
|
El Bezawy, R., Tripari, M., Percio, S., et al. (2020) SPOP Deregulation Improves the Radiation Response of Prostate Cancer Models by Impairing DNA Damage Repair. Cancers, 12, 1462. https://doi.org/10.3390/cancers12061462
|
[41]
|
Siu, M.K., Wong, E.S., Kong, D.S., et al. (2013) Stem Cell Transcription Factor NANOG Controls Cell Migration and Invasion via Dysregulation of E-Cadherin and FoxJ1 and Contributes to Adverse Clinical Outcome in Ovarian Cancers. Oncogene, 32, 3500-3509. https://doi.org/10.1038/onc.2012.363
|
[42]
|
Wong, O.G. and Cheung, A.N. (2016) Stem Cell Transcription Factor NANOG in Cancers—Is Eternal Youth a Curse? Expert Opinion on Therapeutic Targets, 20, 407-417. https://doi.org/10.1517/14728222.2016.1112791
|
[43]
|
Zhang, J., Chen, M., Zhu, Y., et al. (2019) SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression. Developmental Cell, 48, 329-344.e325. https://doi.org/10.1016/j.devcel.2018.11.035
|
[44]
|
Huang, X., Wullschleger, S., Shpiro, N., et al. (2008) Important Role of the LKB1-AMPK Pathway in Suppressing Tumorigenesis in PTEN-Deficient Mice. Biochemical Journal, 412, 211-221. https://doi.org/10.1042/BJ20080557
|
[45]
|
Zadra, G., Photopoulos, C., Tyekucheva, S., et al. (2014) A Novel Direct Activator of AMPK Inhibits Prostate Cancer Growth by Blocking Lipogenesis. EMBO Molecular Medicine, 6, 519-538. https://doi.org/10.1002/emmm.201302734
|
[46]
|
Hirsch, H.A., Iliopoulos, D., Tsichlis, P.N., et al. (2009) Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission. Cancer Research, 69, 7507-7511.
https://doi.org/10.1158/0008-5472.CAN-09-2994
|
[47]
|
Wang, X., Jin, J., Wan, F., et al. (2019) AMPK Promotes SPOP-Mediated NANOG Degradation to Regulate Prostate Cancer Cell Stemness. Developmental Cell, 48, 345-360.e347. https://doi.org/10.1016/j.devcel.2018.11.033
|
[48]
|
Swami, U., Isaacsson Velho, P., Nussenzveig, R., et al. (2020) Association of SPOP Mutations with Outcomes in Men with de Novo Metastatic Castration-Sensitive Prostate Cancer. European Urology, 78, 652-656.
https://doi.org/10.1016/j.eururo.2020.06.033
|
[49]
|
Zhu, Y., Wen, J., Huang, G., et al. (2021) CHD1 and SPOP Synergistically Protect Prostate Epithelial Cells from DNA Damage. Prostate, 81, 81-88. https://doi.org/10.1002/pros.24080
|